Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Instil Bio Inc TIL

Instil Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte (TIL), therapies for the treatment of patients with cancer. It is developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.


NDAQ:TIL - Post by User

Post by CarrFlournoyon Oct 06, 2018 4:08pm
223 Views
Post# 28758003

$5.4 million cash pending

$5.4 million cash pending Till has learned from IGC that all conditions precedent to complete the Transaction, as defined in the Share Purchase Agreement1 , have been fulfilled, and the US $200 million completion consideration has been paid into escrow. The final step towards closing the Transaction is notification by the Russian authorities that ownership of the Russian subsidiary holding the Malmyzh licenses has been transferred to RCC. IGC has indicated that this last step should occur within the next five to ten days. The estimated value of the Transaction to Till’s interest in IGC, net of financial arrangements, is approximately US $5.4 million. Scotiabank Europe plc (“Scotiabank”), the U.K. subsidiary of The Bank of Nova Scotia, is an advisor to IGC regarding the Transaction.
<< Previous
Bullboard Posts
Next >>